Collecting medical information and tissue samples from patients with pancreatic disorders
Official title: Biospecimen Resource for Pancreas Disease, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease
Run by Mayo Clinic · NCT00830557 · Data updated 2026-11-12
This study is collecting medical information and samples from people with pancreatic cancer or other pancreatic disorders to help find better ways to detect and treat these diseases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 3 sites (Phoenix, Arizona and 2 other locations) |
| Status | Recruiting |
| Started | October 1, 2000 |
| Main results expected | August 30, 2027 |
| Study ends | August 30, 2027 |
| Registry record updated | March 9, 2026 |
| Trial ID | NCT00830557 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with known or suspected pancreatic diseases such as pancreatic adenocarcinoma, islet cell cancer, or pancreatitis.
✕Probably not a fit
Patients under 18 years old, those unable to provide informed consent, or prison inmates may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather medical information and collect biospecimens, including blood and tissue samples, from patients diagnosed with pancreatic cancer or other pancreatic disorders. The primary objective is to create a resource bank that facilitates the discovery of biomarkers for risk assessment and early detection of pancreatic diseases. Patients will undergo sample collection and complete questionnaires while their medical records are reviewed to support future research in targeted therapies and screening methods.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and treatment options for patients at risk of pancreatic cancer and other pancreatic disorders.
How similar studies have gone: Other studies have shown success in utilizing biospecimen banks for cancer research, indicating that this approach is promising and has been validated in similar contexts.
Who can join: the full rules
Show full inclusion / exclusion criteria
* Known or suspected pancreas disease including: * pancreas adenocarcinoma * islet cell cancer * pancreatic cysts * pancreatitis (hereditary, acute, or chronic) * Next of kin of deceased participant who did not complete participation before passing away Exclusion Criteria: * Under the age of 18 * Unable to provide informed consent * Prison inmates
Where it's running
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States Recruiting -
Mayo Clinic in Florida
Jacksonville, Florida, United States Recruiting -
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Shounak Majumder, MD — Mayo Clinic
- Study coordinator: Adriana Delgado, MA
- Email: pancreas@mayo.edu
- Phone: 800-914-7962
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using AI for early screening of pancreatic cancer
This study is testing if using artificial intelligence can help find pancreatic cancer earlier in people who are at high risk, like those with new diabetes or family history of the disease.
-
Blood protein biomarkers to help diagnose pancreatic cancer in adults
This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.
-
Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer
This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.
-
Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer
This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.
-
Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer
This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.
-
Odesa Criteria 2026: tests for autoimmune pancreatitis diagnosis
This study checks if the OC26 scoring system can accurately diagnose autoimmune pancreatitis in adults who may have AIP or related pancreatic diseases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.